UBS Group
NVO

UBS Group’s Novo Nordisk NVO Stock Holding History

UBS Group’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$74.2M Buy
2,019,218
+1,166,180
+137% +$55.3M 0.01% 1276
2025
Q4 		$43.4M Sell
853,038
-30,748
-3% -$1.57M 0.01% 1759
2025
Q3 		$49M Buy
883,786
+541,284
+158% +$31.7M 0.01% 1638
2025
Q2 		$23.6M Sell
342,502
-197,872
-37% -$13.5M ﹤0.01% 2203
2025
Q1 		$37.5M Buy
540,374
+415,656
+333% +$34.3M 0.01% 1732
2024
Q4 		$10.7M Buy
124,718
+120,200
+2,660% +$13M ﹤0.01% 2959
2024
Q3 		$538K Sell
4,518
-15,482
-77% -$2.06M ﹤0.01% 5177
2024
Q2 		$2.85M Sell
20,000
-17,500
-47% -$2.32M ﹤0.01% 3396
2024
Q1 		$4.82M Sell
37,500
-207,288
-85% -$24.7M ﹤0.01% 3013
2023
Q4 		$25.3M Buy
+244,788
New +$24.2M 0.01% 1426
2022
Q1 		– Sell
-127,800
Closed -$7.16M – 10694
2021
Q4 		$7.16M Buy
+127,800
New +$6.92M ﹤0.01% 2460
2020
Q3 		– Sell
-16,000
Closed -$524K – 8280
2020
Q2 		$524K Hold
16,000
– – ﹤0.01% 4090
2020
Q1 		$482K Buy
+16,000
New +$476K ﹤0.01% 3989
2019
Q1 		– Sell
-132,200
Closed -$3.04M – 8019
2018
Q4 		$3.04M Buy
132,200
+86,000
+186% +$1.91M ﹤0.01% 2623
2018
Q3 		$1.09M Buy
+46,200
New +$1.13M ﹤0.01% 3770
2018
Q1 		– Sell
-181,800
Closed -$4.88M – 8058
2017
Q4 		$4.88M Buy
+181,800
New +$4.62M ﹤0.01% 2376
2015
Q1 		– Sell
-2,000
Closed -$42K – 9172
2014
Q4 		$42K Buy
+2,000
New +$44.7K ﹤0.01% 6702

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

UBS Group's NVO Position: Q1 2026 in Review

UBS Group reduced its Novo Nordisk (NVO) stake by 7% in Q1 2026, selling an estimated $16.4M and leaving 4,565,708 shares worth $168M. The position accounts for 0.03% of the portfolio, ranked #703.

UBS Group first reported a position in NVO in Q4 2014 and has held it in 46 quarters since. The position peaked at $250M in Q4 2025. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • UBS Group held 4,565,708 shares of Novo Nordisk worth $168M as of Q1 2026.
  • UBS Group sold 346,183 Novo Nordisk shares in Q1 2026, an estimated $16.4M.
  • Novo Nordisk made up 0.03% of UBS Group's portfolio in Q1 2026, its #703 holding.
  • UBS Group first reported a position in Novo Nordisk in Q4 2014 and has held it in 46 quarters since.
  • UBS Group's Novo Nordisk position peaked at $250M in Q4 2025.
  • 1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.